• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

    2/14/24 6:28:12 AM ET
    $MACA
    Blank Checks
    Finance
    Get the next $MACA alert in real time by email
    SC 13G/A 1 tm245838d10_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 3)

     

    Moringa Acquisition Corp.
    (Name of Issuer)
     
    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G6S23K108

    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe Capital Management, L.P.

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    RGC Management Company, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Steven B. Katznelson

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada, United States of America and the United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Christopher Hinkel

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC Master Fund, L.P.

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC GP, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

    Item 1(a).

    Name of Issuer:

    Moringa Acquisition Corp.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    250 Park Avenue, 7th Floor

    New York, NY 11040

       
    Item 2(a). Name of Person Filing:
     

    Radcliffe Capital Management, L.P.

    RGC Management Company, LLC

    Steven B. Katznelson

    Christopher Hinkel

    Radcliffe SPAC Master Fund, L.P.

    Radcliffe SPAC GP, LLC

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:
     

    50 Monument Road, Suite 300

    Bala Cynwyd, PA 19004

     

    Item 2(c). Citizenship:
     

    Radcliffe Capital Management, L.P. – Delaware, United States of America

    RGC Management Company, LLC – Delaware, United States of America

    Steven B. Katznelson – Canada, United States of America and the United Kingdom

    Christopher Hinkel – United States of America

    Radcliffe SPAC Master Fund, L.P. – Cayman Islands

    Radcliffe SPAC GP, LLC – Delaware, United States of America

     

    Item 2(d). Title of Class of Securities:
      Class A ordinary shares, par value $0.0001 per share
       
    Item 2(e). CUSIP Number:
     

    G6S23K108

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)

    Amount beneficially owned:

     

    0 shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    0 shares deemed beneficially owned by RGC Management Company, LLC

    0 shares deemed beneficially owned by Steven B. Katznelson

    0 shares deemed beneficially owned by Christopher Hinkel

    0 shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    0 shares deemed beneficially owned by Radcliffe SPAC GP, LLC

     

      (b)

    Percent of class:

     

    0.00% shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    0.00% shares deemed beneficially owned by RGC Management Company, LLC

    0.00% shares deemed beneficially owned by Steven B. Katznelson

    0.00% shares deemed beneficially owned by Christopher Hinkel

    0.00% shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    0.00% shares deemed beneficially owned by Radcliffe SPAC GP, LLC

     

      (c) Number of shares as to which Radcliffe Capital Management, L.P. has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
           
        Number of shares as to which RGC Management Company, LLC has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0

     

     

     

     

        Number of shares as to which Steven B. Katznelson has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
           
        Number of shares as to which Christopher Hinkel has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
           
        Number of shares as to which Radcliffe SPAC Master Fund, L.P. has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
           
        Number of shares as to which Radcliffe SPAC GP, LLC has:
         
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0
           
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      See Exhibit B attached hereto.

     

     

     

     

    Item 8. Identification and Classification of Members of the Group:
      Not applicable
       
    Item 9. Notice of Dissolution of Group:
      Not applicable
       
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        February 14, 2024
        (Date)
         
    Radcliffe Capital Management, L.P.   /s/ Steven B. Katznelson
    By RGC Management Company, LLC,   Signature
    its General Partner*    
        Steven B. Katznelson
        Managing Member
         
    RGC Management Company, LLC*   /s/ Steven B. Katznelson
        Signature
         
        Steven B. Katznelson
        Managing Member
         
    Steven B. Katznelson*   /s/ Steven B. Katznelson
        Signature
         
         
    Christopher Hinkel*   /s/ Christopher Hinkel
        Signature
         
         
    Radcliffe SPAC Master Fund, L.P.   /s/ Steven B. Katznelson
    By Radcliffe SPAC GP, LLC,   Signature
    its General Partner*    
        Steven B. Katznelson
        Managing Member
         
    Radcliffe SPAC GP, LLC*   /s/ Steven B. Katznelson
        Signature
         
        Steven B. Katznelson
        Managing Member

     

    *The Reporting Person specifically disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

     

    Exhibit A

     

    Agreement

     

    The undersigned agree that this Schedule 13G dated February 14, 2024 to the Class A ordinary shares, par value $0.0001 per share of Moringa Acquisition Corp. shall be filed on behalf of the undersigned.

     

        February 14, 2024
        (Date)
         
    Radcliffe Capital Management, L.P.   /s/ Steven B. Katznelson
    By RGC Management Company, LLC,   Signature
    Its General Partner    
        Steven B. Katznelson
        Managing Member
         
    RGC Management Company, LLC   /s/ Steven B. Katznelson
        Signature
         
        Steven B. Katznelson
        Managing Member
         
    Steven B. Katznelson   /s/ Steven B. Katznelson
        Signature
         
         
    Christopher Hinkel   /s/ Christopher Hinkel
        Signature
         
         
    Radcliffe SPAC Master Fund, L.P.   /s/ Steven B. Katznelson
    By Radcliffe SPAC GP, LLC,   Signature
    its General Partner    
        Steven B. Katznelson
        Managing Member
         
    Radcliffe SPAC GP, LLC   /s/ Steven B. Katznelson
        Signature
         
        Steven B. Katznelson
        Managing Member

     

     

     

     

    Exhibit B

     

    Radcliffe Capital Management, L.P. is the relevant entity for which RGC Management Company, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons. Radcliffe SPAC Master Fund, L.P. is the relevant entity for which Radcliffe SPAC GP, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons.

     

     

     

    Get the next $MACA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition Corp

      SCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      8/27/24 11:00:41 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 15-12G filed by Moringa Acquisition Corp

      15-12G - Moringa Acquisition Corp (0001835416) (Filer)

      8/26/24 9:49:09 AM ET
      $MACA
      Blank Checks
      Finance
    • Moringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Moringa Acquisition Corp (0001835416) (Filer)

      8/21/24 4:05:08 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)

      4 - Moringa Acquisition Corp (0001835416) (Issuer)

      8/24/23 2:31:41 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 3: New insider Hudson Bay Capital Management Lp claimed ownership of 401,271 units of Class A Ordinary Shares

      3 - Moringa Acquisition Corp (0001835416) (Issuer)

      4/5/23 4:59:51 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

      Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

      9/9/24 7:32:00 AM ET
      $MACA
      $SLXN
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

      MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

      8/15/24 4:05:00 PM ET
      $MACA
      Blank Checks
      Finance
    • Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                             Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

      2/22/24 8:27:00 AM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/14/24 6:28:12 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/12/24 4:24:57 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/8/24 1:16:56 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance